Buy Anti-Human MDA5/IFIH1 Polyclonal Antibody

Catalog No.

PHJ51904

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human MDA5/IFIH1 (Arg309-Asp1025).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

MDA-5, IFIH1, Helicard, Clinically amyopathic dermatomyositis autoantigen 140 kDa, Interferon-induced with helicase C domain protein 1, Helicase with 2 CARD domains, RNA helicase-DEAD box protein 116, RIG-I-like receptor 2, Interferon-induced helicase C domain-containing protein 1, MDA5, Murabutide down-regulated protein, Melanoma differentiation-associated protein 5, CADM-140 autoantigen, RH116, RLR-2

Purification

Purified by antigen affinity column.

Accession

Q9BYX4

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Western Blot

Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with MDA5/IFIH1 antibody (PHJ51904) at 1 μg/ml.

Lane 1: Recombinant protein

Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

Predict MW: 96 kDa
Observed MW: 96 kDa

Response to "two cases of ulcerative dermatomyositis with negative antimelanoma differentiation-associated gene 5 antibody"., PMID:40503549

Dual Autoimmunity: A Case Report of the Sequential Development of Systemic Lupus Erythematosus in a Patient With Anti-MDA5 Dermatomyositis., PMID:40486387

Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia., PMID:40470565

Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis., PMID:40470551

Anti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report., PMID:40419927

Spontaneous Intramuscular Hemorrhage in Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis., PMID:40416002

Long-term outcomes in lung transplant for anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody positive interstitial lung disease: a case series., PMID:40397104

A Diagnostic Uncertainty in an Immunocompromised Patient: Rapidly Progressive Interstitial Lung Disease vs. Pneumocystis Pneumonia., PMID:40376365

The Role of Anti-MDA5 Antibodies in Rapidly Progressive Interstitial Lung Disease: A Case Report and Literature Review., PMID:40370246

Successful Management of Occult Breast Cancer with a Background of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Pneumonia: A Case Report., PMID:40352963

Anti- Melanoma Differentiation-Associated Gene 5 Antibody Positive Dermatomyositis: Recent Progress in Pathophysiology and Treatment., PMID:40323493

Slowly Progressive Melanoma Differentiation-Associated Gene 5 (MDA-5) Interstitial Lung Disease Following COVID-19 Infections: A Pulmonary Puzzle., PMID:40322373

Generation of an induced pluripotent stem cell (iPSC) line (INNDSUi0010-A) from a patient with Anti-MDA5 antibody-positive dermatomyositis., PMID:40250126

The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis., PMID:40246682

Analysis of the immune response in COVID-19., PMID:40246347

Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis., PMID:40244469

Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis., PMID:40241163

MDA5 protein mediating persistent ER stress/unfolded protein response contributes to endothelial-mesenchymal-transition of lung microvascular endothelial cell in dermatomyositis., PMID:40122798

Nailfold videocapillaroscopy findings are associated with IIM subtypes and IFN activation., PMID:40114239

Amyopathic dermatomyositis associated with immune checkpoint inhibitor therapy in lung adenocarcinoma: a case report., PMID:40104725

Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease., PMID:40102365

Comparison of Chest High-Resolution Computed Tomography Findings in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive and Antibody-Negative Progressive Pulmonary Fibrosis with Polymyositis/Dermatomyositis., PMID:40095548

Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report., PMID:40070519

External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China., PMID:40056481

Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib., PMID:40001174

Clinical Features of Dermatomyositis Associated with Myositis-Specific Antibodies in Moroccan Patients., PMID:39996701

Case report: Exploring efficacy of tofacitinib in modulating interferon response in five case of anti-MDA5+ dermatomyositis with interstitial lung disease., PMID:39967677

Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study., PMID:39959646

Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease., PMID:39948593

Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort., PMID:39915831

Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil., PMID:39914261

Mortality Risk Prediction in Patients With Antimelanoma Differentiation-Associated, Gene 5 Antibody-Positive, Dermatomyositis-Associated Interstitial Lung Disease: Algorithm Development and Validation., PMID:39908093

Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study., PMID:39907594

Frequent, perseverant therapy with plasma exchange in Japanese patients with rapidly progressive interstitial lung disease caused by anti-MDA5 antibody-positive dermatomyositis: A report of two cases., PMID:39904755

Monocyte-macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti-melanoma differentiation-associated gene 5-positive dermatomyositis-related interstitial lung disease., PMID:39902678

Clinical Characteristics and Outcomes of Patients with Anti-MDA5 Antibody Associated Rapidly Progressive Interstitial Lung Disease (RP-ILD): A Case Series., PMID:39886293

Pneumomediastinum in MDA5+ Dermatomyositis: A Case Series., PMID:39886283

Anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease masquerading as rheumatoid arthritis-associated interstitial lung disease or overlapping with the same: a phenomenon driven by a probable genetic predisposition., PMID:39883306

Pulmonary and serum cytokine profiles of patients with anti-ARS and anti-MDA5 antibodies., PMID:39881471

Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study., PMID:39863893

Predictive value of myositis antibodies: role of semiquantitative classification and positivity for more than one autoantibody., PMID:39837620

[Cutaneous ulceration in dermatomyositis : Case reports with positive anti-NXP-2/anti-TIF1-gamma antibody status]., PMID:39820721

Amyopathic Dermatomyositis with a Rapidly Progressing Interstitial Pneumonia., PMID:39790853

Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort., PMID:39789667

Increased Risk of Myositis-Specific and Myositis-Associated Autoantibodies After COVID-19 Pandemic and Vaccination: A Spanish Multicenter Collaborative Study., PMID:39767707

Uncommon concurrent pulmonary infections: Aspergillus fumigatus and Lomentospora prolificans in an Anti-MDA5 antibody-positive dermatomyositis patient., PMID:39760058

Anti-MDA5 Positive Juvenile Dermatomyositis With Macrophage Activation Syndrome: A Case Report., PMID:39759739

[Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with idiopathic inflammatory myopathy]., PMID:39757095

Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies., PMID:39751977

Two case reports of MDA5-type seronegative dermatomyositis., PMID:39717688

Document Download

Anti-Human MDA5/IFIH1 Polyclonal Antibody.pdf

Anti-Human MDA5/IFIH1 Polyclonal Antibody